

**FRONT**

**Apixaban 5 mg film-coated tablets** **Patient Alert Card**

**This card should be with you / the child / the caregiver at all times**  
**Show this card to your pharmacist, dentist and any other healthcare professionals before treatment. I am under anticoagulation treatment with Apixaban 5 mg film-coated tablets to prevent blood clots**  
**Please complete this section or ask your doctor to do it**

Name: \_\_\_\_\_ Birth Date: \_\_\_\_\_  
 Indication: \_\_\_\_\_ Weight: \_\_\_\_\_  
 Dose: \_\_\_\_\_ mg twice daily  
 Doctor's Name: \_\_\_\_\_ Doctor's telephone: \_\_\_\_\_

**Information for patients**

- Take/give Apixaban regularly as instructed. If you miss a morning dose, take/give it as soon as you remember and it may be taken/given together with the evening dose. A missed evening dose can only be taken/given during the same evening. Do not take/give two doses the next morning, instead continue to follow your dosing schedule twice daily as recommended on the next day.
- Do not stop taking/giving Apixaban without talking to your doctor, as you are/the patient is at risk of suffering from a stroke/blood clot or other complications.

**BACK**

- Apixaban helps to thin your blood. However, this may increase the risk of bleeding.
- Signs and symptoms of bleeding include bruising or bleeding under the skin, tar-coloured stools, blood in urine, nose-bleed, dizziness, tiredness, paleness or weakness, sudden severe headache, coughing up blood or vomiting blood.
- If the bleeding does not stop on its own, **seek medical attention immediately.**
- If you/the patient need surgery or any invasive procedure, inform the healthcare provider that you are/the patient is taking Apixaban.

**Information for healthcare professionals**

- Apixaban is an oral anticoagulant acting by direct selective inhibition of factor Xa.
- Apixaban may increase the risk of bleeding. In case of major bleeding events, it should be stopped immediately.
- Treatment with Apixaban does not require routine monitoring of exposure. A calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations, e.g., overdose and emergency surgery (prothrombin time (PT), international normalised ratio (INR) and activated partial thromboplastin time (aPTT) clotting tests are not recommended) – see SmPC.
- An agent to reverse the anti-factor Xa activity of apixaban is available for adults, however, its safety and efficacy have not been established in paediatric patients (refer to the summary of product characteristics of andexanet alfa).

**Artwork Proof Box:**

Variation:	V024 – Reference product adaption + closing sequence	<b>Technical Colours:</b>
Proof no:	002.1	 Legend:
Date prepared:	02/08/2025	 Cutting:
Font size:	6 pt	
Fonts:	FuturaCEEF	
Dimensions:	75 x 45 mm	
<b>Technical data:</b>		
SKUs:	00000000	
SZ codes:	SZ0000000000	
Item codes:	00000000	<b>Colours:</b>
Pharma codes:	00000000	 Pantone 541



**Signature Panel:**
